R&D On CB1s as an alternative to GLP-1s, with Punit Dhillon In a new pharmaphorum podcast, Punit Dhillon, CEO of Skye Bioscience, discusses CB1 inhibitor antibodies in the obesity space.
News Appeal finds NICE must reconsider Alzheimer's drugs Lilly and Eisai's bid to secure NHS coverage of their Alzheimer's therapies has entered a new phase, after an appeal of last year's rejection by NICE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
